Open an account

Abivax SA

ABVX · NYSE

$88.01−$2.22 (−2.46%)TodayMarket closed ·
Prev close $90.23

About ABVX

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. The company is headquartered in Paris, Ile-De-France and currently employs 68 full-time employees. The company went IPO on 2015-06-26. ABIVAX utilizes RNA-protein interaction interference and cytotoxic TH1 cell amplification to generate therapies to help patients clear viruses like HIV, HBV and HPV. The firm's product pipeline comprises ABX 203, which is the therapeutic vaccine candidate obtained from the Centre for Genetic Engineering and Biotechnology, Cuba (CIGB) and is intended for patients with chronic hepatitis B disease; and ABX196, the adjuvant for therapeutic vaccines, among others.

Employees
80
Headquarters
Paris, Ile-De-France
Listed
Jun 26, 2015
Sector
Health Care
Industry
Biotechnology
Website
abivax.com

ABVX key statistics

Market cap
7.15B
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.28M
Volume
431.90K
Open price
$89.60
High today
$89.60
Low today
$87.03
52 Week high
$148.83
52 Week low
$69.81

Abivax SA (ABVX) at a glance

Abivax SA (ABVX) last traded at $88.01, with a market cap of 7.15B and a price-to-earnings ratio of 0.00.

Today the stock has traded between $87.03 and $89.60. The current price is 1.1% above the day's low and 1.8% below its high.

Volume so far is 431.90K shares, below the average of 1.28M shares a day.

Over the past year Abivax SA has ranged from $69.81 to $148.83, and now sits 23% of the way up that range.

Abivax SA met or beat analyst EPS estimates in 2 of the last 7 quarters. In Q2 FY26 it reported -$2.09 per share against an estimate of -$1.83.

The average analyst price target is $168.07, 91.0% above the current price, from 13 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

92%of 13 analyst ratings say Buy
  • Buy92.3%
  • Hold7.7%
  • Sell0.0%
Price target · 11 analystsAvg $168.07
Low
$78.36
Now
$88.01
High
$209.48

ABVX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 2 of the last 7 quarters, by 21.0% on average.

  1. Q2 FY17: reported -$0.57 per share against an estimate of -$0.8772
  2. Q4 FY22: reported -$2.39 per share against an estimate of -$1.80
  3. Q2 FY24: reported -$1.29 per share against an estimate of -$1.39
  4. Q4 FY24: reported -$1.50 per share against an estimate of -$1.37
  5. Q2 FY25: reported -$1.59 per share against an estimate of -$1.58
  6. Q4 FY25: reported -$3.24 per share against an estimate of -$1.52
  7. Q2 FY26: reported -$2.09 per share against an estimate of -$1.83

ABVX news

  • 10 Health Care Stocks With Whale Alerts In Today’s Session

  • 10 Health Care Stocks With Whale Alerts In Today’s Session

  • 10 Health Care Stocks Whale Activity In Today’s Session

  • 10 Health Care Stocks Whale Activity In Today’s Session

  • Avi Kapoor

    Nasdaq Gains Over 300 Points; Chicago PMI Falls In June

  • Vandana Singh

    Why Is Abivax Stock Skyrocketing Tuesday?

  • 10 Health Care Stocks With Whale Alerts In Today’s Session

  • Press releaseGlobe Newswire

    ABVX Investors Have Opportunity to Join Abivax S.A. Fraud Investigation with the Schall Law Firm

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.